 Cost-effectiveness HMG-CoA reductase inhibition primary secondary prevention coronary heart disease cost-effectiveness HMG-CoA coenzyme reductase inhibitors lovastatin primary secondary prevention coronary heart disease Coronary Heart Disease Policy Model computer-stimulated model risk factor-specific annual incidence coronary heart disease risk recurrent coronary events persons prevalent coronary heart disease secondary prevention mg/d lovastatin lives costs men cholesterol levels mg/dL mmol/L favorable cost-effectiveness ratio regardless cholesterol level young women cholesterol levels mg/dL mmol/L Doses mg/d lovastatin favorable incremental cost-effectiveness ratios men cholesterol levels mg/dL mmol/L comparison primary prevention favorable cost-effectiveness ratios subgroups cholesterol levels risk factors current national recommendations medication secondary prevention aggressive projections recommendations use medications primary prevention cost medication risk factor profile individual patient